WertQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMMittelzufluss aus Investitionstätigkeit793 K-375 K-38 K-241 K-715 K-1.37 MZahlungsströme aus der Finanzierungstätigkeit675 K45 K116.95 M130 K159.06 M276.18 MFreier Cashflow-12.13 M-19.68 M-33.94 M-32.55 M-35.55 M-121.71 M
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.